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Abstract
Background: Recent microarray and sequencing studies of prostate cancer
showed multiple molecular alterations during cancer progression. It is critical to
evaluate these molecular changes to identify new biomarkers and targets. We
performed analysis of glycine‐N‐acyltransferase like 1 (GLYATL1) expression in
various stages of prostate cancer in this study and evaluated the regulation of
GLYATL1 by androgen.
Method: We performed in silico analysis of cancer gene expression profiling and
transcriptome sequencing to evaluate GLYATL1 expression in prostate cancer.
Furthermore, we performed immunohistochemistry using specific GLYATL1
antibody using high‐density prostate cancer tissue microarray containing primary
and metastatic prostate cancer. We also tested the regulation of GLYATL1 expression
by androgen and ETS transcription factor ETV1. In addition, we performed RNA‐
sequencing of GLYATL1 modulated prostate cancer cells to evaluate the gene
expression and changes in molecular pathways.
Results: Our in silico analysis of cancer gene expression profiling and
transcriptome sequencing we revealed an overexpression of GLYATL1 in
primary prostate cancer. Confirming these findings by immunohistochemistry,
we show that GLYATL1 is overexpressed in primary prostate cancer compared
with metastatic prostate cancer and benign prostatic tissue. Low‐grade
cancers had higher GLYATL1 expression compared to high‐grade prostate
tumors. Our studies showed that GLYATL1 is upregulated upon androgen
treatment in LNCaP prostate cancer cells which harbors ETV1 gene rearrange-
ment. Furthermore, ETV1 knockdown in LNCaP cells showed downregulation
of GLYATL1 suggesting potential regulation of GLYATL1 by ETS transcription
factor ETV1. Transcriptome sequencing using the GLYATL1 knockdown
prostate cancer cell lines LNCaP showed regulation of multiple metabolic
pathways.
Conclusions: In summary, our study characterizes the expression of GLYATL1 in
prostate cancer and explores the regulation of its regulation in prostate cancer
showing role for androgen and ETS transcription factor ETV1. Future studies are
needed to decipher the biological significance of these findings.
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1 | INTRODUCTION
Prostate cancer (PCa) is the most prevalent cancer entity in men with
an estimated 174 650 new cases in 2019 in the USA. Despite recent
advances in diagnosis and treatment, it remains the second most
cancer‐related cause of death.1 Recent molecular studies have paved
the way to a better understanding of the underlying biology of tumor
growth and progression. This offers new possibilities to find new
therapeutic targets for the disease.2,3
GLYATL1 encodes an enzyme that catalyzes arylacetyl
transfer.4,5 In noncancerous tissue it was found to be highly
expressed in liver and kidney, and to a lesser extent in pancreas,
testis, ovary and stomach.6 Human glycine N‐acyltransferases
(GLYATL, GLYATL1, GLYATL2, and GLYATL3) are involved in
conjugation of carboxylic acids to glycine and glutamine. This
conjugation is thought to be a part of a pathway for the
detoxification of benzoate and other xenobiotics.7 GLYAT plays
a major role in liver metabolism. It regulates mitochondrial
adenosine triphosphate (ATP) production, glycine availability,
CoASH (Coenzyme A) availability and the detoxification of
various organic acids.7-9 Human GLYATL2 conjugates medium‐
and long‐chain saturated and unsaturated acyl‐CoA esters to
glycine producing N‐oleoyl glycine and N‐arachidonoyl glycine.
The latter are structurally and functionally related to endocan-
nabinoids and have been identified as signaling molecules that
regulate functions such as the perception of pain and body
temperature. They have also been found to have anti‐inflamma-
tory properties.10 Furthermore, GLYATL2 was found to be a
target of ETS transcription factor ETV1, which is along with other
ETS transcription factors rearranged in ∼50% of human prostate
cancer cases.11,12
Microarray studies have shown that in breast cancer, GLYATL1
was among genes differently expressed in the contralateral un-
affected breast in women with estrogen‐receptor‐negative compared
with those with estrogen‐receptor positive breast cancer.13 In
prostate cancer cell lines GLYATL1 was shown to play a role in
colony forming ability.14 To date, its expression in cancerous tissue
and its role in tumorigenesis is not well understood.
In this study, we sought to analyze the expression and regulation
of GLYATL1 in prostate cancer. Our investigation suggests that
GLYATL1 is overexpressed in low‐grade disease. Furthermore,
we show that androgen treatment and ETS transcription factor
ETV1 plays a role in regulating its expression.
2 | MATERIALS AND METHODS
2.1 | Gene expression from the Cancer Genome
Atlas
Gene expression levels of GLYATL1 in normal prostate and prostate
adenocarcinoma were interrogated utilizing UALCAN (http://ualcan.
path.uab.edu), a web portal providing the Cancer Genome Atlas
(TCGA) RNA sequencing data in the form of boxplots, depicting
gene expression levels.15
2.2 | Prostate tissue samples
Benign and prostate cancer tissues were obtained from radical
prostatectomy series and from the Rapid Autopsy Program at the
University of Michigan through appropriate informed consent.
Institutional Review Board approval was obtained to procure and
analyze the tissues. Two tissue microarrays including 134 patients
were constructed with a total of 321 TMA spots.
2.3 | Immunohistochemistry
Immunohistochemistry (IHC) was carried out to evaluate GLYATL1
expression using rabbit polyclonal antibody against GLYATL1
(catalog #HPA039501, 1:200; Sigma‐Aldrich, MO). Formalin‐fixed,
paraffin‐embedded tissue sections were deparaffinized and rehy-
drated. Antigen retrieval was performed by boiling the slides for
10minutes in citrate buffer (catalog #C9999‐1000ML; Sigma‐
Aldrich). Immunostaining was performed using the Vector Labora-
tories staining kit following the manufacturer’s protocol. Endogenous
peroxidase activity was blocked using BLOXALL Blocking Solution
(catalog #SP‐6000; Vector Laboratories). Nonspecific binding sites
were blocked by incubation with normal horse serum (R.T.U., 2.5%,
catalog #S‐2012; Vector Laboratories). Primary antibody was added
in a 1:200 dilution for 1.5 hours at room temperature according to
dilution protocol optimized in our laboratory. After washing with
phosphate buffer saline (PBS), secondary antibody (anti‐rabbit,
catalog #MP‐7401; Vector Laboratories) was added for 45minutes
at room temperature. Following two washings (5minutes each) with
PBS and PBS‐T, antibody signals were detected using ImmPACT DAB
(catalog #SK‐4105; Vector Laboratories). Hematoxylin QS (catalog #
H‐3404; Vector Laboratories) was used as a counterstain. Sections
were then dehydrated.
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2.4 | Immunohistochemical scoring system
GLYATL1 IHC expression was evaluated by a genitourinary patholo-
gist. The scoring system consisted of a modified quantitative H‐score
system (ranging from 0 to 300) in which GLYATL1 expression was
estimated as the products of the intensity (0 for negative, 1 for weakly
positive, 2 for moderately positive, and 3 for strongly positive)
multiplied by the extent of the staining in the tumor cells (0% to
100%). GLYATL1 score is reported by diagnosis and by Gleason
score. Each sample core was plotted with multiple cores per patient.
The mean, 95% confidence intervals, and pairwise t test P values
reported were adjusted for the correlation among multiple samples
per patient using a clustered analysis. The analysis for Figure 3 was
generated using SAS software. Copyright© 2016 SAS Institute Inc, SAS
and all other SAS Institute Inc, product or service names are registered




F IGURE 1 The human N‐acytransferase GLYATL1 shows increased expression in prostate cancer. A, Gene expression profiling analysis of
multiple prostate cancer datasets using Oncomine database shows higher GLYATL1 expression in primary prostate cancer compared with
benign prostate tissue across the datasets (The rank for a gene is the median rank for that gene across each of the analyses. The P value for a
gene is its P value for the median ranked analysis). B, Transcriptome sequencing of prostate cancer. GLYATL1 expression in benign, primary, and
metastatic prostate cancer were measured in transcript per million utilizing the TCGA Data set. C, Expression of GLYATL1 in normal prostate,
primary and metastatic tumor samples using the data set by Grasso et al. D, GLYATL1 expression analysis per Gleason score utilizing the TCGA
data set. E, Expression of the human glycine N‐acyltransferases (GLYATL1, GLYATL2, GLYATL3, and GLYAT) in primary prostate cancer and
normal prostate tissue. GLYATL1, glycine‐N‐acyltransferase like 1; PCa, prostate cancer [Color figure can be viewed at wileyonlinelibrary.com]
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2.5 | Western blot analyses
For Western blot analysis, protein samples were, as previously
described,16 separated on sodium dodecyl sulfate polyacrylamide
gel electrophoresis (4‐12%; Invitrogen). Equal amounts of proteins
were loaded and transferred for 2 hours at 0.35A onto an
Immobilon1‐P polyvinylidene fluoride (PVDF) membrane (EMD
Millipore, Billerica, MA). To block nonspecific binding, the
membrane was incubated for 1 hour in blocking buffer (Tris‐
buffered saline, 0.1% Tween 20 [TBS‐T], 5% nonfat dry milk)
followed by incubation overnight at 4°C with the primary
antibody. After two washes with TBS‐T for 5 minutes, the blot
was incubated with horseradish peroxidase‐conjugated secondary
antibody (1:5000) for 1 hour at room temperature. The membrane
was again washed with TBS‐T and TBS twice for 5 minutes each
and signals were visualized by Luminata Crescendo chemilumines-
cence Western blot analysis substrate as per manufacturer’s
protocol (EMD Millipore). For loading control β‐actin was applied.
Therefore the membrane was incubated, after two washes with
TBS‐T, with the anti‐β‐actin antibody for 1 hour at room
temperature. After again two washings with TBS‐T and TBS
signals were visualized, as described above, using Luminata
Crescendo chemiluminescence Western blot analysis substrate
as per manufacturer’s protocol (EMD Millipore). Antibodies used
in the study are anti‐GLYATL1 (catalog # HPA039501, 1:1000;
Sigma‐Aldrich), anti‐PSA rabbit polyclonal antibody (Dako Den-
mark A/S 1:1000; Dako), anti‐HRP‐β‐actin (catalog # HRP‐60008,
1:20 000; PTG Labs, Rosemont, IL), anti‐rabbit IgG HRP (catalog #
SA00001‐2, 1:5000; PTG Labs, Rosemont). All antibodies were
employed at dilutions optimized in our laboratory.
F IGURE 2 Immunohistochemical staining of GLYATL1 in prostate. A, benign prostate tissue; B, high‐grade prostatic intraepithelial neoplasia;
C, D, Gleason score 6 prostate cancer; E, Gleason score 8 prostate cancer; F, liver metastasis of prostate cancer (arrow) showing low or no
staining of GLYATL1. Scale bars = 50 µm in (A, B, C, E, and F); 20 µm in (D). GLYATL1, glycine‐N‐acyltransferase like 1 [Color figure can be
viewed at wileyonlinelibrary.com]
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2.6 | Cell culture
Human prostate cancer cell lines LNCaP, C4‐2B, 22Rv1, PC3, DU145,
and VCaP, as well as RWPE‐1, were obtained from ATCC. LNCaP,
C4‐2B, 22Rv1, PC3 and DU145 cells were cultivated at 37°C in RPMI
medium (Gibco RPMI 1640 Medium [+] L‐Glutamine, Life Technol-
ogies) supplemented with 10% fetal bovine serum and 100 U/mL
penicillin G and 100 μg/mL streptomycin in a humidified environment
with 5% CO2. VCaP cells were cultivated at 37°C in Dulbecco
Modified Eagle’s medium +GlutaMAX (Gibco DMEM(1×) + Gluta-
MAX, Life Technologies) supplemented with 10% fetal bovine serum
and 100U/mL penicillin G and 100 μg/mL streptomycin (Life
Technologies) in a humidified environment with 5% CO2. RWPE‐1
cells were cultivated in Keratinocyte Serum Free Medium (Gibco Life
Technologies) supplemented with 2.5 µg EGF (Gibco Life Technolo-
gies) and 25mg Bovine Pituitary Extract (Life Technologies) and
100U/mL penicillin G and 100 μg/mL streptomycin (Life Technolo-
gies) in a humidified environment with 5% CO2. Normal prostate
epithelial cells (PrEC) were obtained from Clonetics Corporation
(San Diego, CA) and were maintained in prostate epithelial cell
medium (PrEGM) supplemented with a mixture of various growth
factors (SingleQuots) (Clonetics); and 10% fetal bovine serum.
2.7 | GLYATL1 and ETV1 knockdown in prostate
cancer cells
ETV1 and nontargeting small interfering RNA (siRNA) were obtained
from Dharmacon, (Lafayette, CO) and transfection experiments were
performed followed the manufacturer's protocol. For transfection
Lipofectamine RNAi MAX reagent (Thermo Fisher) was applied. Cells
were seeded 1 × 105 in a six‐well plate and simultaneously
transfected with siRNA. Twenty‐four hours later a second identical
transfection was performed. Cells were harvested 72 hours after the
first transfection for RNA isolations and Western blot experiments.
siRNA used in this study are shown in Table ST1.
Stable knockdowns were created using short hairpin RNA
(shRNA) purchased from SBI (System Biosciences, Mountain View,
CA; see Table ST2). Lentiviruses for creating these stable knock-
downs were created by the University of Alabama at Birmingham
(A) (B)
(C)
F IGURE 3 Higher expression of GLYATL1 in primary prostate cancer. A, Immunohistochemical score of GLYATL1 in benign prostate tissue,
high‐grade prostatic intraepithelial (PIN), primary tumors and metastasis. B, analysis of GLYATL1 immunohistochemical score in primary
prostate cancer per Gleason score. C, Western Blot analysis of GLYATL1 using benign prostate tissue, primary and metastatic prostate cancer
samples. GLYATL1, glycine‐N‐acyltransferase like 1 [Color figure can be viewed at wileyonlinelibrary.com]
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Vector Core. After infection of prostate cells with lentiviruses
expressing GLYATL1 shRNA or nontargeting shRNA, stable knock-
down cell lines were generated by selection with 1 µg/mL puromycin
(Life Technologies).
2.8 | RNA extraction and real‐time polymerase
chain reaction
Total RNA from prostate cancer cells was extracted by using Direct‐
zol RNA MiniPrep Plus kit (Zymo Research) according to the
manufacturer’s protocol. RNA from tissue was harvested by employ-
ing the Qiagen RNAeasy kit. Each sample was transcribed into
complementary DNA (cDNA) by using Superscript III Reverse
Transcriptase (ThermoFischer Scientific), deoxynucleoside tripho-
sphates, and random hexamer primers (ThermoFischer Scientific).
For each real‐time polymerase chain reaction (RT‐PCR) amplification,
2 µL of cDNA (200 ng/µL) product, 5 µL SYBR green PCR Master Mix
(Applied Biosystems), 1 µL primer solution, and 2 µL of DNAse/
RNAse free water was added for a final volume of 10 µL.
Thermocylcling conditions were as suggested by the manufacturer:
95° for 20 seconds to activate the polymerase followed by 40 cycles
of 95° for 15 seconds and 60° for 1minute. SYBR green was used
to determine the messenger RNA (mRNA) expression level of a
gene of interest. Levels were normalized to beta‐Actin using the
ΔΔCt method. All primers for SYBR green were synthesized by
Integrated DNA Technologies (Coralville, IA) and listed in Table ST3.
All PCRs were performed in triplicates.
2.9 | Transcriptome sequencing analyses
RNA from prostate cancer cells (22Rv1 and LNCaP) treated with
GLYATL1 shRNA and nontargeting shRNA were sequenced using
Illumina sequencer. The raw sequence reads obtained as FASTQ files
were trimmed using Trim Galore (v0.4.1) (http://www.bioinformatics.
babraham.ac.uk/projects/trim_galore/) to remove adapter sequences
and low‐quality reads. After performing the quality control analysis
using FastQC (v0.11.5) (http://www.bioinformatics.babraham.ac.uk/
projects/fastqc/), the trimmed reads were mapped to the human
genome (GRCh38/hg38) using TopHat v2.1.0.17 The aligned reads
were sorted via samtools (Version: 1.3.1).18 HTSeq‐count (version
0.6.0)19 was used to obtain raw read counts for each annotated
human gene. Differential expression analysis between GLYATL1
shRNA and nontargeting shRNA treated samples was carried out
using DESeq20 considering “blind” method for estimating dispersion
and “fit‐only” sharing mode. Genes with an absolute fold change
of 1.5 or more and P < .05 were considered as differentially
expressed [DEG]. Gene ontology and Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway enrichment analysis on
differentially expressed genes were performed using online platform
DAVID (Database for Annotation, Visualization, and Integrated
Discovery) version 6.8.21 Volcano plots and heatmap were
generated in R 3.2.2 (https://cran.r‐project.org/) using gplots package
[https://cran.r‐project.org/web/packages/gplots/index.html].
2.10 | Accession numbers
The RNA sequencing data are submitted to the Gene Expression
Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession
no. GSE130395).
2.11 | ChIP sequencing and promoter analyses
AR binding in the GLYATL1 promoter region in prostate cancer
cells (LNCaP) treated with dihydrotestosterone (DHT) was explored.
SRA files corresponding to GSE8386022 and GSE9234723 were
downloaded. Table S4 shows a complete list of raw data downloaded
and processed. Downloaded SRA files were converted to FASTQ
files using SRA Toolkit (https://www.ncbi.nlm.nih.gov/sra/docs/
toolkitsoft/). ChIP‐seq raw data were processed as mentioned in
Chakravarthi et al.24 The upstream region of GLYATL1 and KLK3
(as positive control) was explored for AR binding using Integrative
Genome Viewer (IGV).25
AR peak sequence located within GLYATL1 promoter region
was extracted, and scanned for AR position weight matrix (PWM)
(MA0007.2) using JASPAR database.26 Details of AR ChIP‐seq raw
data files downloaded from NCBI Sequence Read Archive (SRA)
database are shown in Table ST4.
2.12 | Statistical analysis
GLYATL1 expression index (EI) from tissue microarrays was reported
by tissue diagnosis and Gleason score separately. Expression index
equals the intensity expression score multiplied by the percent of
cells displaying the expression. Each sample core was plotted with
multiple cores per patient. The mean, 95% confidence intervals, and
pairwise t test P values reported were adjusted for the correlation
among multiple samples per patient using a clustered analysis. The
statistical analysis of the tissue microarray immunohistochemistry
data was generated using SAS software. Copyright© 2016 SAS
Institute Inc. SAS and all other SAS Institute Inc. product or service
names are registered trademarks or trademarks of SAS Institute Inc,
Cary, NC, USA.
Statistical analysis for cell proliferation study was performed by
using JMP® 13.1.0. To determine significant differences between
two groups, the Wilcoxon rank sum test was applied for continuous
variables. P < .05 were considered significant.
3 | RESULTS
3.1 | GLYATL1 is overexpressed in low grade
and localized prostate cancer
Based on our in silico analysis of publicly available prostate
cancer gene expression data using the Oncomine database
(Oncomine Platform; Life Technologies, Ann Arbor, MI)27 we found
GLYATL1 to be overexpressed in human prostate adenocarcinomas
in seven independent gene expression profiling studies (Figure 1A)
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(P = 1.78E−5).28-33 By applying the Oncomine database and the
web portal UALCAN15 it could be shown that GLYATL1 was
significantly overexpressed in human prostate cancer compared to
benign prostate tissue in the study by Lapointe et al31 (See Figure
S1A) and the TCGA study cohort2 (P = 1.624E−12) (Figure 1B). The in
silico analysis of the study by Grasso et al revealed an overexpression
of GLYATL1 in primary prostate cancer compared to benign tissue
and metastatic tumors (Figure 1C). Furthermore, GLYATL1 was
especially overexpressed in the lower grade tumors in the TCGA
study cohort (Figure 1D). Looking at the three other Human Glycine
N‐acyltransferases (GLYATL2, GLYATL3, and GLYAT) revealed that
the observed overexpression in prostate cancer was unique for
GLYATL1 (Figure 1E).
3.2 | Immunohistochemical and Western blot
analyses of GLYATL1 in prostate cancer tissue
Using a GLYATL1 specific antibody, we performed immunohisto-
chemistry staining on TMAs containing benign prostatic tissue,
prostatic intraepithelial neoplasia (PIN), localized and metastatic
prostate cancer. Representative staining patterns are depicted in
Figure 2. The arrow in the Figure 2F shows the prostate cancer liver
metastasis showing the absence of GLYATL1 expression. TMA
analyses showed an increased GLYATL1 protein expression in line
with our in silico analysis of GLYATL1 mRNA. GLYATL1 is over-
expressed especially in localized prostate tumors compared to
normal prostatic tissue (P < .0001), PIN (<.0001) and metastatic
prostate cancer (P < .0001) (Figure 3A and 3B). Analyses of a subset
of prostatic adenocarcinomas based on grade showed a higher
GLYATL1 expression in Gleason score 5, 6, and 7 tumors compared
with those with Gleason score 8 and 9. Furthermore, Western Blot
experiments revealed that GLYATL1 protein was present primarily in
localized prostate cancer and metastases, and it was not detectable
in benign tissue (Figure 3C).
3.3 | GLYATL1 expression is regulated by androgen
and ETV1
RT‐PCR (Figure 4A) and Western blot analysis (Figure 4B) displayed
that GLYATL1 is expressed in the androgen receptor (AR) containing
prostate cancer cell lines LNCaP, C4‐2B, 22Rv1, and VCaP. It was
absent in prostate epithelial cells and RWPE‐1 (resembling cells of
benign prostatic hyperplasia), as well as PC3 and DU145, which lack
androgen receptor expression. After treating LNCaP with 5 nM
Methyltrienolone (R1881) and 10 nM DHT for 48 hours, levels of
GLYATL1 mRNA were increased compared with GLYATL1 levels in
nontreated or vehicle‐control cells (Figure 4C). Similarly, mRNA
expression levels of the androgen‐regulated gene prostate‐specific
antigen (PSA) were increased (Figure 4D). Western blot analysis
showed similar results (Figure 4E). Analyses of AR ChIP‐seq data in
DHT treated LNCaP revealed AR occupancy in the GLYATL1
promoter region (Figure 4F, Figure S2B), indicating GLYATL1 as an
AR target. Furthermore, GLYATL1 was decreased upon ETV1
knockdown in LNCaP cells (Figure 4G).
3.4 | Molecular pathways altered by GLYATL1
modulation in prostate cancer cells
To investigate the signaling events that are regulated by GLYATL1,
we performed GLYATL1 knockdown using a specific shRNA targeting
GLYATL1 in prostate cancer cell lines LNCaP and 22Rv1. The
knockdown in LNCaP was confirmed by RT‐PCR and Western blot
(Figure 5B). Transcriptome sequencing was performed using RNA
from GLYATL1 knockdown (GLYATL1 shRNA) as well as control cells.
Figure 5A shows the top 40 up‐ and downregulated genes upon
GLYATL1 knockdown in LNCaP cells. Our analysis identified that
upon GLYALT1 knockdown, 164 protein‐coding genes were down-
regulated and 105 protein‐coding genes were upregulated (Figure
5C). Table S5 and S6 provide the up and downregulated genes in
22Rv1 and LNCaP cells after GLYATL1 knockdown. Table S7 and S8
provide the biological processes and KEGG pathways altered upon
GLYATL1 knockdown in these cells. KEGG pathways enriched in
differentially expressed genes on GLYATL1 knockdown includes
glycolysis and gluconeogenesis as well as hypoxia‐inducible factor 1
(HIF‐1) signaling, metabolic pathways and central carbon metabolism
in cancer (Figure 5D).
Knockdown confirmation, top up‐ and downregulated genes, as
well as KEGG pathways enriched after GLYATL1 knockdown in
22Rv1 are shown in Figure S1B‐SD.
4 | DISCUSSION
In this study, we evaluated the expression and regulation of Glycine‐
N‐Acyltransferase Like 1 in prostate cancer. GLYATL1 as an enzyme,
involved in N‐acyl amino acid production and metabolism, is normally
expressed in liver and kidney.6,7 Microarray studies have shown its
overexpression in prostate cancer.5,14,34,35 Our in silico analysis
further indicates, GLYATL1 transcripts to be higher in localized
prostate cancers compared with benign prostatic tissue and meta-
static prostate cancer. Especially the lower Gleason grade tumors
(≤7) showed a high GLYATL1 expression. This was further confirmed
by Western blot analysis and immunohistochemistry, showing
GLYATL1 protein expression to be low in benign prostate tissue,
PIN and most of the metastatic prostate cancers.
To evaluate the potential role of GLYATL1 in prostate cancer, we
analyzed its expression in prostate cancer cell lines. In their study on
next‐generation RNAseq in castration‐resistant prostate cancer cell
lines, Ma et al36 found GLYATL1 among the top 8 downregulated
genes in PC3 and DU145 (which represent acquired resistance to
androgens) vs LNCaP cells. In line with that, we found GLYATL1 to be
present in prostate cancer cell lines that express AR (LNCaP, C4‐2B,
VCaP, and 22Rv1) and absent in DU145, PC3, benign prostate
epithelial cells and RWPE‐1. Our analyses further identified that
GLYATL1 expression is induced by androgen treatment in LNCaP
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cells. ChIP‐Seq data analyses showed AR binding in the promoter
region of the GLYATL1 gene, emphasizing a direct regulation of
GLYATL1 by androgen signaling. As prostate cancer growth is
initially androgen‐dependent, the gold‐standard treatment option
for advanced disease is androgen deprivation.37 However, most
patients eventually develop resistance and disease progression.
Thus, several studies have investigated signaling events that lead
to castration‐resistant prostate cancer (CRPC).30,38,39 Kaushik et al38
have recently shown, that glucosamine‐phosphate N‐acetyltransfer-





F IGURE 4 GLYATL1 expression is regulated by androgen and ETV1. A, B, Western blot analysis and quantitative reverse transcription
polymerase chain reaction analysis of GLYATL1 in prostate cancer cell lines. C, D, GLYATL1 and prostate‐specific antigen (PSA) mRNA
expression in untreated, vehicle control treated (ethanol [ETOH]), and androgen‐treated (dihydrotestosterone [DHT], methyltrienolone
[R1881]) LNCaP cells. E, Western blot analysis of GLYATL1 in androgen‐treated LNCaP cells. F, IGV output representing the gene neighborhood
region of GLYATL1, showing AR ChIP‐seq peaks in the proximal promoter region in LNCaP cells treated with dihydrotestosterone. AR ChIP‐seq
data from Malinen et al22 (GSE83860) were used. Peaks annotated using Homer shown in the topmost lane. AR peak sequence
(Chr11:58926274‐58926649) with AR consensus (highlighted in the pink font) shown below. G, GLYATL1 expression in ETV1 knockdown
LNCaP cells. GLYATL1, glycine‐N‐acyltransferase like 1 [Color figure can be viewed at wileyonlinelibrary.com]
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(A) (B) (C)
(D)
F IGURE 5 RNA sequencing analysis of GLYATL1 knockdown in LNCaP cells. A, Heatmap showing top 40 up‐ and downregulated genes after
GLYATL1 knockdown in LNCaP cells. B, Western blot analysis and real‐time polymerase chain reaction confirmation of GLYATL1 knockdown in
LNCaP cells. C, Volcano plot showing distribution of differentially expressed genes on GLYATL1 knockdown in LNCaP cells. Log2 fold change is
represented in x‐axis, while y axis represents –log10 P value. Gene upregulated are marked with red dots, while blue dots indicate genes
downregulated. D, Bar plot showing top 10 KEGG pathways enriched in genes differentially expressed on GLYATL1 knockdown in LNCaP cell
line. GLYATL1, glycine‐N‐acyltransferase like 1 [Color figure can be viewed at wileyonlinelibrary.com]
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is significantly decreased in CRPC compared with localized prostate
cancer. Similarly, we found GLYATL1 to be lower in metastatic
prostate cancer. Whether this expression pattern has a role for
GLYATL1 in the development of CRPC remains to be investigated.
As mentioned above, chromosomal rearrangements involving ETS
transcription factors, such as ERG and ETV1, are the most frequent
alterations in prostate cancer. Translocations place the coding
regions of the latter mentioned genes under the control of
androgen‐responsive promoters, such as TMPRSS2.40 ETV1 expres-
sion in ETV1 knock‐in mice was found to positively cooperate with
AR signaling, leading to additional enhancement of expression of AR
targets.41 In line with this mechanism, we found GLYATL1 not only to
be upregulated upon androgen treatment, but also downregulated in
LNCaP cells following ETV1 knockdown, indicating a potential
regulatory role for this ETS transcription factor in GLYATL1
expression.
Serum level of PSA is a widely used screening biomarker.42
However, PSA elevation is not very specific for prostate cancer, as
numerous benign conditions, like benign prostatic hyperplasia, can
cause a rise in its serum levels. Therefore, there is a need for
additional risk stratification. In this setting, urine as a liquid biopsy
platform is actively being investigated. In a study by Leyten et al35
GLYATL1, along with 15 other biomarkers, was described to be
differentially expressed in urine sediments from prostate cancer
patients compared to healthy controls. This further emphasizes
GLYATL1’s potential as an early stage biomarker.
To understand the pathways that may be regulated by
GLYATL1, we performed RNA sequencing using shRNA specifically
targeting GLYATL1 in prostate cancer cell lines. Pathway
analysis in LNCaP GLYATL1 knockdown cells revealed a potential
involvement in metabolic pathways including glycolysis. Anaerobic
glycolysis has been shown to be one of the main metabolic
changes in CRPC‐like cells.43 Whether GLYATL1 knockdown
could be similarly implicated in driving LNCaP cells towards a
more aggressive phenotype will require further assessment and
could then provide a rational for our finding of lower GLYATL1
levels in metastatic tumors compared to localized prostate
cancers.
In summary, our study further characterizes the expression
GLYATL1 in prostate cancer and explores its regulation. We show
GLYATL1 overexpression mainly in low grade and localized prostate
cancer. Additionally, our findings indicate that androgen and ETV1
are involved in its regulation. Future studies are needed to decipher
the biological significance of these findings.
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